Ulrike M. Heber

Ulrike M. Heber

Auto-generated profile, based on publicly available information

Ulrike M. Heber

Department of Pathology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in Science Advances
Verified
Journal Article
Closed access
SHStefan Heber
Stefan Heber
FRFelix Resch
Felix Resch
CCCosmin I. Ciotu
Cosmin I. Ciotu
AGAndreas Gleiss
Andreas Gleiss
UHUlrike M. Heber
Ulrike M. Heber
MFMichael J.M. Fischer
Michael J.M. Fischer
Sensing of noxious heat has been reported to be mediated by TRPV1, TRPA1, TRPM3, and ANO1 in mice, and this is redundant so that the loss of one receptor is at least partially compensated for by others. We have established an infusion-based human heat pain model. Heat-induced pain probed with antagonists for the four receptors did not match the redundancy found in mice. In healthy participants, only TRPV1 contributes to the detection of noxious heat; none of the other three receptors are involved. TRPV1 inhibition reduced the pain at all noxious temperatures, which can also be seen as an increase in the temperature that causes a particular level of pain. However, even if the TRPV1-dependent shift in heat detection is about 1°C, at the end of the temperature ramp to 52°C, most heat-induced pain remains unexplained. This difference between species reopens the quest for the molecular safety net for the detection of noxious heat in humans.

5 August 2025 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
MSMyriam Stolz
Myriam Stolz
Alex FarrAlex Farr
Alex Farr
KTKristina A. Tendl-Schulz
Kristina A. Tendl-Schulz
FFFlorian Frommlet
Florian Frommlet
HRHelga Reckendorfer
Helga Reckendorfer
ZBZsuzsanna Bagó-Horváth
Zsuzsanna Bagó-Horváth
Novel human epidermal growth factor receptor 2 (HER2)-directed therapies have significantly improved outcomes for patients with HER2-positive early-stage breast cancer. Our study assessed the impact of HER2/chromosome enumeration probe 17 ( CEP17 ) ratio on residual cancer burden (RCB) and long-term prognosis following neoadjuvant chemotherapy with dual HER2-targeted therapy using trastuzumab and pertuzumab to identify candidates for chemotherapy de-escalation. Our study included 169 patients with primary invasive HER2-positive breast cancer who received neoadjuvant chemotherapy with trastuzumab and pertuzumab at the Medical University of Vienna from 2014 to 2020. HER2 (ERBB2) gene copy number and HER2/CEP17 ratio were assessed by in situ hybridization. RCB and pathologic complete remission (pCR) served as primary and secondary endpoints, respectively. Univariate and multivariate logistic regression models were applied to analyze associations between outcomes and predictor variables, focusing on the predictive role of HER2/CEP17 ratio, with cutoff values estimated. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan–Meier method. HER2/CEP17 ratio was significantly associated with response to dual-targeted neoadjuvant chemotherapy in primary HER2-positive breast cancer. Optimal HER2/CEP17 cutoff for predicting RCB 0/I was identified at 5.19. HER2/CEP17 ratio was also significantly associated with PFS as a continuous predictor. Multivariate analysis showed that hormone receptor status and the presence of an in situ tumor component significantly influenced therapy response. HER2/CEP17 ratio predicts therapy response and therefore might aid patient stratification for therapy de-escalation with respect to dual neoadjuvant HER2 blockade. Further investigations are warranted to confirm its relevance with other HER2-targeted agents.

28 May 2021
Verified
Book Chapter
Closed access
PDF file
UHU. M. Heber
U. M. Heber
WWW. J. Weninger
W. J. Weninger